marketwatch: "new migraine drugs have promise -- and a ,500 price tag.".

another new drug in the migraine pipeline is lasmiditan. it works the same way as triptans. but unlike the triptans, it doesn't constrict.

the data also revealed 66% of trusts who replied had at least one cancer patient forced to wait over six months to start treatment, and 69% had a worse longest wait than in 2010..